Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Arsenic trioxide (As(2)O(3)) is highly efficacious for acute promyelocytic leukemia (APL). Environmental arsenic exposure predisposes to malignancies, but the risk for therapeutic arsenic is undefined. Three APL patients (de novo, 2; therapy-related, 1) in a cohort of 59 cases given oral-As(2)O(3) for induction and maintenance treatment developed secondary cancers (nasopharyngeal carcinoma, 2; colonic adenocarcinoma, 1) at 16, 36 and 55 months post-As(2)O(3) therapy. Retrospective analysis of biomarkers (Epstein Barr virus serology and quantification, carcinoembryonic antigen) showed the potential presence of cancers before or shortly after As(2)O(3) therapy, suggesting that As(2)O(3) had not initiated these malignancies. Compared against matched background population, there was an increased risk of second cancer (p=0.012, standard incidence ratio=6.5; 95% confidence interval=1.4-19.0).
Au
Wing-Yan
WY
Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.
Kumana
Cyrus R
CR
Lam
Ching-Wan
CW
Cheng
Vincent C C
VC
Shek
Tony W
TW
Chan
Eric Y T
EY
Liu
Rico
R
Kwong
Yok-Lam
YL
D000230:Adenocarcinoma / Q000139:chemically induced*; D000328:Adult; D000368:Aged; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000139:chemically induced*; D005260:Female; D006131:Growth Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000139:chemically induced*; D009369:Neoplasms / Q000139:chemically induced*; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use*
D001152:Arsenicals; D006131:Growth Inhibitors; D010087:Oxides; D000077237:Arsenic Trioxide